애클라리온ACON 주가

SentinelOne To Rally Nearly 40%? Here Are 10 Analyst Forecasts For Friday

Top Wall Street analysts changed outlook on top names. For full changes, see analyst ratings page. Stock targets and ratings also updated.

Ascendiant Capital Maintains Buy on Aclarion, Raises Price Target to $7.5

Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the price target from $7 to $7.5.

Echo Lake Capital Offers To Acquire Aclarion At $4.00/Share And Contingent Value Right Representing Right For Stockholders To Receive 80% Of Net Proceeds From Nociscan Sale.

Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse takeoverStock price

Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate

Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.55) by 13.55 percent. This is a 85.62 percent increase over losses of $(9.32) per share from the same

[10-Q] 분기 실적 — FORM 10-Q FOR MAR 2026

♻️ 재탕[4] 내부자 거래

♻️ 재탕[4] 내부자 거래

♻️ 재탕[4] 내부자 거래

[4] 내부자 거래

Aclarion Adds Lanman Spinal Neurosurgery As Clinical Site In CLARITY Trial

Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex spinal procedures, early adoption of innovative technologies and high surgical volumeThe CLARITY randomized